Description
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by guests Thomas Tadros, MD, and Ashraf Sabe, MD, of Brigham and Women's Hospital, to discuss efficacy and safety of hybrid epicardial and endocardial ablation versus endocardial ablation in patients with persistent and longstanding persistent atrial fibrillation. In this randomized trial, hybrid surgical and catheter ablation was more effective than catheter ablation alone in persistent atrial fibrillation without significant procedural risk increase.
Learning Objectives
- To discuss the findings of "Efficacy and safety of hybrid epicardial and endocardial ablation versus endocardial ablation in patients with persistent and longstanding persistent atrial fibrillation: a randomised, controlled trial."
Article Authors and Podcast Contributors
Article Authors
Nicolas Doll, Timo Weimar, Dariusz A. Kosior, Alan Bulava, Ales Mokracek, Gerold Mönnig, Jonathan Sahu, Steven Hunter, Maurits Wijffels, Bart van Putte, Norman Rüb, Petr Nemec, Tomas Ostrizek, and Piotr Suwalskii
Podcast Contributors
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital
Thomas Tadros, MD, of Brigham and Women's Hospital
Ashraf Sabe, MD, of Brigham and Women's Hospital
Disclosure Policy
ACE Disclosure Policy
The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company* within the 24 months prior to the disclosure.
Any individual who refuses to disclose financial relationships is disqualified from participating in HRS ACE-certified activities. Owners and employees of ACCME-defined ineligible companies may have no role in the planning or implementation of ACE activities without a special written exemption from the HRS Chief Learning Officer that will be granted only in specific circumstances that meet ACCME requirements.
ACCME Definition:
*An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Examples of such organizations include:
- Advertising, marketing, or communication firms whose clients are ineligible companies
- Bio-medical startups that have begun a governmental regulatory approval process
- Compounding pharmacies that manufacture proprietary compounds
- Device manufacturers or distributors
- Diagnostic labs that sell proprietary products
- Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
- Manufacturers of health-related wearable products
- Pharmaceutical companies or distributors
- Pharmacy benefit managers
- Reagent manufacturers or sellers
All relevant financial relationships have been mitigated.Host Disclosure(s):
W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic
Contributor Disclosure(s):
T. Tadros: No relevant financial relationships with ineligible companies to disclose.
A. Sabe: No relevant financial relationships with ineligible companies to disclose.
Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose.
S. Sailor: No relevant financial relationships with ineligible companies to disclose.